NXTC NextCure, Inc.

Nasdaq nextcure.com


$ 6.72 $ 0.37 (5.83 %)    

Tuesday, 14-Oct-2025 15:59:14 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 6.72
$ 6.50
$ 5.50 x 350
$ 6.85 x 100
$ 6.32 - $ 6.80
$ 2.69 - $ 19.20
16,110
na
17.98M
$ 0.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 06-10-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nextcure-q2-eps-1129-misses-039-estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) b...

 us-stocks-likely-to-open-on-a-mixed-note-intel-philips-66-centene-charter-earnings-in-focus

U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.

 nextcure-stock-skyrockets-nearly-45-in-after-hours-trading-after-sharing-preclinical-data-for-brittle-bone-disease

NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical da...

 nextcure-presented-new-preclinical-data-in-a-well-established-model-of-osteogenesis-imperfecta--demonstrating-that-treatment-with-nc605-achieved-improved-bone-microarchitecture-and-reduced-fracture-incidence-compared-to-anti-sclerostin-treatment

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company com...

 piper-sandler-maintains-overweight-on-nextcure-lowers-price-target-to-15

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $3...

 nextcure-enacts-1-for-12-reverse-stock-split-shares-begin-trading-today-on-adjusted-basis

On July 14, 2025, NextCure, Inc., a Delaware corporation (the "Company"), effected a one-for-twelve (1:12) reverse stoc...

 nextcure-and-ligachembio-announces-they-will-present-trial-in-progress-poster-for-lncb74-a-b7-h4-targeted-antibody-drug-conjugate-as-monotherapy-in-participants-with-advanced-solid-tumors-at-american-society-of-clinical-oncology-2025

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and...

 nextcure-q1-eps-039-beats-040-estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 2...

 hc-wainwright--co-reiterates-buy-on-nextcure-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $3 price target.

 hc-wainwright--co-reiterates-buy-on-nextcure-lowers-price-target-to-3

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $...

 nextcure-fy-2024-gaap-eps-199-misses-192-estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(1.92) by...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION